Why the study?
Current SARS-CoV-2 variants evade authorized monoclonal antibodies and threaten serum-neutralizing efficacy elicited by vaccination or infection, urging the development of antivirals against SARS-CoV-2 and related sarbecoviruses.
Population
One five-dose vaccinated donor and golden Syrian hamsters
Comparison
Prophylactic administration of selected neutralizing antibodies vs viral challenge
Design
Preclinical laboratory and animal challenge study
Authors
Loading...
May inform pan-coronavirus antibody development; leaves open clinical translation pending validation.
Sequential COVID-19 vaccination can induce broadly neutralizing antibodies that protect against diverse SARS-CoV-2 variants and related sarbecoviruses in preclinical models.
Zhao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: